NCT05680454 2023-01-17A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV VaccineBeijing Health Guard Biotechnology, IncPhase 1 Completed160 enrolled
NCT03384316 2020-09-09Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced CancerNational Institutes of Health Clinical Center (CC)Phase 1 Completed11 enrolled 18 charts